Showing 4061-4070 of 10105 results for "".
- FDA Clears CellFX System for the Treatment of SHhttps://practicaldermatology.com/news/fda-clears-cellfx-system-for-the-treatment-of-sh/2461358/The U.S. Food and Drug Administration (FDA) granted Pulse Bioscience’s CellFX System (FDA) 510(k)marketing clearance for the treatment of sebaceous hyperplasia in patients with Fitzpatrick skin types I-II. This specific indication clearance enhances the CellFX
- CHMP Recommends Adtralza (tralokinumab) for the Treatment of Adolescents With Moderate-to-Severe ADhttps://practicaldermatology.com/news/chmp-recommends-adtralza-tralokinumab-for-the-treatment-of-adolescents-with-moderate-to-severe-ad/2461351/The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) is recommending extending the approval of LEO Pharma’s Adtralza (tralokinumab) to include adolescents aged 12 to 17 with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic
- Third Harmonic Bio Appoints Thomas M. Soloway to its Board of Directorshttps://practicaldermatology.com/news/third-harmonic-bio-appoints-thomas-m-soloway-to-its-board-of-directors/2461292/Thomas M. Soloway is now a member of Third Harmonic Bio, Inc.’s Board of Directors. Mr. Soloway brings more than 25 years of experience in the life sciences industry, with senior roles in strategy, operations, corporate finance and venture capital to the company,
- First Patient Enrolled in UNION Therapeutic’s Study of Orismilast MR tablet in ADhttps://practicaldermatology.com/news/first-patient-enrolled-in-union-therapeutics-study-of-orismilast-mr-tablet-in-ad/2461288/The first patient has been enrolled in ADESOS, a Phase 2b dose-finding study evaluating the safety and efficacy of UNION therapeutic’s orismilast MR tablet in adult patients with moderate to severe AD. The purpose of the study is to identify the appropria
- Tarek El Hoss Named Sr. Vice President of Market Development and Sales at MedXhttps://practicaldermatology.com/news/tarek-el-hoss-named-sr-vice-president-of-market-development-and-sales-at-medx/2461287/Tarek El Hoss is MedX Health Corp.’s New Senior Vice President, Market Development and Sales. Mr. El Hoss will oversee strategic global growth initiatives and will be responsible for the deployment of market development strategies to impact immediate revenue generation and g
- FDA Clears Soligenix's Synthetic Hypericin for Phase 2 Clinical Trial in Psoriasishttps://practicaldermatology.com/news/fda-clears-soligenixs-synthetic-hypericin-for-phase-2-clinical-trial-in-psoriasis/2461250/The U.S. Food and Drug Administration (FDA) has cleared Soligenix’s Investigational New Drug (IND) application for a Phase 2a clinical trial of topically-applied SGX302 (synthetic hypericin). Patient enrollment is slated to begin in the fourth quarter of 2022. "Duri
- FDA Approves Sol-Gel Technologies' and Galderma's Epsolay for Rosaceahttps://practicaldermatology.com/news/fda-approves-sol-gel-technologies-and-galdermas-epsolay-for-rosacea/2461170/The FDA has approved Sol-Gel Technologies' Epsolay, a proprietary cream formulation of benzoyl peroxide, 5%, for the treatment of inflammatory lesions of rosacea in adults. The benzoyl peroxide in Epsolay is encapsulated within silica-based patented microcapsules. The silica-based s
- Castle's Non-Invasive Gene Expression Profile Test Can Predict Response to Systemic Therapy in Patients with Inflammatory Skin Diseaseshttps://practicaldermatology.com/news/castles-gene-expression-profile-test-can-predict-response-to-systemic-therapy-in-patients-with-inflammatory-skin-diseases/2461163/Castle Biosciences, Inc.’s non-invasive skin scraping technique produces sufficient ribonucleic acid (RNA) to assess reproducible gene expression for its inflammatory skin disease pipeline test, according to a poster was presented at the 4th Annual Revolutionizing Atopic Der
- Phase 2b Study: AOBiome Therapeutics' Topical B244 Improves Itch, ADhttps://practicaldermatology.com/news/phase-2b-study-aobiome-therapeutics-topical-b244-improves-itch-ad/2461086/AOBiome Therapeutics’ B244 showed positive results from for both Pruritus and Atopic Dermatitis, according to a Phase 2b trial. AOBiome's B244 platform is a patented, proprietary, topical and intranasal formulation. Once deployed, B244 produces nitric
- Leadership Changes Take Place at SkinCeuticalshttps://practicaldermatology.com/news/leadership-changes-at-skinceuticals/2461069/Stephanie Kramer is now SkinCeutical’s Global General Manager, and Amy Sloan is the Head of SkinCeuticals U.S, the company reports Sloan brings 15 years of global and U.S. beauty industry experience - 10 of those years with SkinCeuticals - to the role of Head o